Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

While the condition can impact quality of life and mental health, seeking treatment and support can make a powerful ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

The study compared the risk and cumulative incidence of requiring glaucoma surgery—such as minimally invasive surgery, ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today ann ...

Astria Therapeutics, Inc. ( (ATXS) ) has released its Q3 earnings. Here is a breakdown of the information Astria Therapeutics, Inc. presented ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...